DOCSLIB.ORG

The Barbiturates in Forensic Chemistry Dissertation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Barbiturates in Forensic Chemistry Dissertation THE BARBITURATES IN FORENSIC CHEMISTRY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy- in the Graduate School of The Ohio State University EQr GWENDOLYN BERTHA CARSON, B« S., M* A* The Ohio State University 195U Approved by* Department of Physiological Chemistry ___________ i TABLE OP CONTENTS page A« Introduction 1 B» Historical 1. The Barbiturates ---------------- 2 2* Barbiturate Poisoning - - -------------------- U a) Deaths due to Barbiturates in Pour Counties and the United States - - ------ ----- 11 b) Doses of Barbiturates in Grains - - -- - - 16 3* Barbiturate Regulations------- - ------------ 21 C. Isolation of the Barbiturates ----- --- - - --- - 2h D» Qualitative Tests for Barbiturates ----- — - ---- 26 E. Quantitative Methods for Barbiturates -------- 28 F* Examination of Tissues --- — 30 1# Degradation Products of Barbiturates ------ 3 1 2a Percent Recovery of Unchanged Barbiturates - - - 3^ G. Experimental Procedures --------------- 35 1* Effect of 5$ Potassium Hydroxide on Barbiturates- 36 2 . Effect of 20$ Acetic Acid on Barbiturates - - - - 38 3. Effect of Water on Salts of Barbituric Acids - - 38 k» Barbiturates Extracted from Liver with 5$ Potassium Hydroxide - — ___ ip. 5. Barbiturates Extracted from Liver with 20$ Acetic A c i d ------------------------------- Hi 6 . Barbiturates Extracted from Liver at pH 1 0 HU 7. Refractive Indices of Barbiturates - ------- H6 8 . Barbiturate-Cyanide Reaction ---------------- 50 9» Effect of Atmospheric Conditions on Barbiturates- £2 H* Discussion --- 53 I* Summary ----- - — — ---- — ------------ 63 J. Conclusion — --------- — ------- 6 H K. Bibliography----------------------------------- 6 6 Iw Autobiography--------------- 73 i i LIST OF TABLES page Table I Formulae of Barbituric Acids - ----- 6 Table II Names and Synonyms of Barbituric Acids - - - - 9 Table III Patent Data for Barbituric Acids - - ---- 10 Table IV Deaths due to Barbiturates in New York City - - - - 1 1 Table V Deaths due to Barbiturates in Franklin County, Ohio 12 Table VI Deaths due to Barbiturates in Cuyahoga County, Ohio 13 Table VII Deaths due to Barbiturates in Los Angeles County, California - -- -- -- -- -- -- -- -- -- - lit Table VIII Deaths due to Barbiturates in 1+8 States -------- 15 Table IX Doses of Barbituric Acid Derivatives in Grains - - 16 Table X Minimum Quantity of Barbiturate found in Tissues in Poison Cases ------------------- 20 Table XI Degradation Products Reported for some Barbiturates 31 Table XII Percent Recovery of Unchanged Barbiturates from Urine 3 k Table XIII Melting Points of Barbituric Acids Recovered after 2 k Hour Treatment with 5$ Potassium Hydroxide - - - 37 Table XIV Melting Points of Barbituric Acids Recovered after 2 k Hour Treatment with 20% Acetic Acid - 39 Table XV Melting Points of Barbituric Acids Recovered from their Salts after 2 k Hour Treatment with Distilled W a t e r --- UO Table XVI Melting Points of Barbituric Acids Recovered from Barbiturate-Liver Mixtures after 2 k Hour Treatment with 5$ Potassium Hydroxide - ----- k2 Table XVII Melting Points of Barbituric Acids Recovered from Barbiturate-Liver Mixtures after 2 k Hour Treatment with 2C$ Acetic A c i d ---------- - 1+3 Table XVIII Melting Points of Barbituric Acids Recovered from Barbiturate-Liver Mixtures after 2i+ Hour Treatment at pH 10 - - - -------- 1+5 ill LIST OF TABLES (continued) page Table XTX Melting Points of Pure Barbituric Acids ----- I46 Table XX(a) Refractive Indices of Barbituric Acids - --- U7 Table XX(b) Refractive Indices of Barbituric Acids - - --- H8 Table XX(c) Temperatures at which Refractive Indices were Measured --- k9 Table XXI Melting Points of Materials Recovered from the Barbituric Acid-Cyanide Reaction Mixtures - - - - $1 Table XXII Melting Points of Barbituric Acids after Exposure to Atmospheric Conditions at Room Temperature - - $2 i v ACKNOWLEDGEMENT The author wishes to acknowledge the assistance of Dr* Clayton S* Sbiith, her preceptor and Chairman of the Department of Physiological Chemistry and the helpful suggestions of Dr* Helen L* Wikoff, Associate Professor of Physiological Chemistry, in carrying out this investigation She also wishes to acknowledge receipt of statistical data on deaths due to barbiturates from the Coroner's Office in New York City; Cuyahoga County, Ohio and Los Angeles County, California. The author also wishes to acknowledge gifts of the following barbituric acid derivatives used in making the determinations investi­ gated in this dissertation; Allyl-n-butyl barbituric acid; Butethal; Ethyl allyl barbituric acid; Mosidal; Pentobarbital; Phenobarbital and Pentothal from Abbott Laboratories. Nostal; Pemoston and Sigmodal from Ames Company, Inc* Dial from Ciba Pharmaceuticals, Inc* Alurate from Hofftaan-La Roche, Inc* Amobarbital and Secobarbital from Eli Lilly and Company* Rutonal from May and Baker, Ltd., Dagenham, England* Butisol from McNeil Laboratories, Inc* Ortal from Parke, Davis and Company, Sandoptal from Sandoz Pharmaceuticals* Delvinal froip Sharp and Dohme, Inc* Ipral from E. R. Squibb and Sons and Cyclobarbital; Evipal and Mephobarbital from Winthrop-Steams, Inc* THE BARBITUATES IN FORENSIC CHEM ISTRY A.’ INTRODUCTION Forensic chemistry may he defined as chemistry applied to the solution of legal problems which may arise in connection with the administration of justice* This field covers the application of chemistry to both criminal and civil investigations*1 The forensic chemist may be called upon to examine blood stains; clothing; counterfeit coins; documents; dusts; various types of fibers; strings and ropes; hairs and textiles, in addition to making chemical analyses of drugs, medicines and vital organs# Of the numerous drugs and medicines which might be involved in forensic chemistry, the sedatives are by far the most important* The most widely used present day sedatives are the barbiturates# With the advent of the barbiturates, the older hypnotics such as chloroform, chloral hydrate, paraldehydes and urethanes have only a limited use«' A study of accidental and suicidal deaths occurring in Los Angeles County during the fiscal year 19£3-195>U reveals more then 2h% increase in deaths due to barbiturates since 19k9 -1 9 $ 0 * It is obvious that with barbiturates involved in so many medicolegal cases, accurate methods for th9 detection of these compounds in tissue, blood and urine should be developed*1 While some of the barbiturates are readily detected by the older methods, others defy detection due principally to the fact that they are metabolized in the body and methods for the detection of the metabolites have not yet been developed in all cases#4 This being the fact, the present investigation was undertaken to -2- iraprove old methods or to develop new ones for the detection of the various barbiturates* B. HISTORICAL 1* The Barbiturates Malonylurea, prepared by Conrad and Gutzeit in 1882, was supposedly naned after a 'Miss Barbara".* Other theories as to the name are (1) that Baeyer called the compound barbituric acid because he considered it to be a "key" to a series of such compounds and (2 ) that the name was selected because the compound was prepared on a St* Barbara's Feast Day * Barbituric acid, which is a combination of urea and malonic acid, forms the basic structure for this series of compounds* The two hydrogen atoms at position $ in barbituric acid are quite reactive and may be replaced by various radicals (R and R*). The bar­ biturates may be named according to the substituent groups in position 5. _________ HYPNOPHORE GROUP HN - C = 0 H !HN -_C « 0 B? ^ \ / S ~ X / HO - Cx ^ C \ HO - Cx C ’ N - C - 0 H - C = 0 i_ JRJ, Barbituric Acid Disubstituted Barbituric Acid The first disubstituted barbituric acid derivative to be prepared was the diethyl compound made by Snil Fischer and J* von Mering in 1903 and later patented under the name "VERONAL"* The compound was VERONAL from the Latin word "vera" because Fischer believed it to be 2 3 the true hypnotic and introduced it as a hypnotic In 1903 • This compound has been officially known as BARBITAL since 1926 * Further investigations established the fact that substitution of dissimilar hydrocarbon groups on the side chain produced compounds which had clinical advantages over BARBITAL*1 The next barbiturate to appear was phenylettyl barbituric acid, prepared by Horlein in 1911* This compound, also known as PHENOBARBITAL, was introduced therapeutically several years after BARBITAL Tinder the trade name of WLtMINALH but became official at the same time as barbital in 19264** HN - C - 0 C,HS / \ / HO - C n N - C^* O f ij PHENOBARBITAL 6 In 191o , the parent compound was modified by having one of the radicals, an ethyl group and the other a methyl butyl group*1 This product known as PENTOBARBITAL or NMBUTAL was developed by the Abbott Laboratories*' AMYTAL developed by the Eli Lilly Company in 1921 was shovm in 1930 6 v by Shonle, et al and Volwiler, et al to be an isomer of PENTOBARBITAL•' These compounds had the same empirical formula but the methyl group in the alkyl side chain of AMYTAL was linked to the/carbon atom whereas, the methyl group was attached to the a carbon in PENTOBARBITAL^ HN - C » 0 C2HB HN • C - 0 C2HB / 2 s ^ \ / 36 - HO ~ C' X / \ (a) w \ / V«>, s N - C^" 0 CH2«CH2-CH"CH3CH2«CH2**CH"CH3 'N -• C^-C'« 0 c h -(c2) h 2)2-c h 3 I t c h 3 c h 3 AMYTAL PENTOBARBITAL In later years several other barbiturates were synthesized and marketed for clinical use* Table I shows some of these compounds,
Load more

Recommended publications
  • Forensic Chemistry (4 Credit Hrs) Course Description: Surve
    CHEMISTRY 107 FORENSIC CHEMISTRY BULLETIN INFORMATION CHEM 107 – Forensic Chemistry (4 credit hrs) Course Description: Surveys chemical aspects of criminal investigation and adjudication including drug, arson, DNA, paint, and fiber identification. Note: Three lecture and three laboratory hours per week. SAMPLE COURSE OVERVIEW This course is an introduction to forensic chemistry intended for non-science majors. The course examines the many ways that chemical principles and scientific techniques are applied in modern crime investigation: the chemical characteristics of fuels and explosives as well as arson-related methods; other ways of identifying criminals through chemical processes, including blood and bodily fluid analyses, the chemical characteristics found in paints, fibers, hair, DNA, and fingerprinting; and the chemical properties of drug analysis. Through readings, lectures, demonstrations, homework, and laboratory exercises, students learn the fundamentals of forensic chemistry and its applications in crime investigation and adjudication. Student learning is evaluated through exams, assignments, participation in class discussions and activities, a case study project, and laboratory reports. ITEMIZED LEARNING OUTCOMES Upon successful completion of CHEM 107, students will be able to: 1. Demonstrate understanding of the scientific method. 2. Discuss the basic principles, concepts, terms, and scientific techniques associated with forensic chemistry. 3. Evaluate the relationships between science, technology, and society as these affect forensic issues. By specifically being able to: Identify steps of scientific method; describe and perform various forensic analytical techniques. Explain the characteristics of fuels and explosives, and their chemical evidence. Classify drugs, identify their chemical properties, and conduct their analysis. Describe the characteristics and properties of various materials such as hair, paint, polymers, fibers.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Determination of Barbiturates and 11-Nor-9-Carboxy-Δ9-THC in Urine
    Determination of Barbiturates and 11-Nor-9-carboxy- 9-THC in Urine using Automated Disposable Pipette Extraction (DPX) and LC/MS/MS Fred D. Foster, Oscar G. Cabrices, John R. Stuff, Edward A. Pfannkoch GERSTEL, Inc., 701 Digital Dr. Suite J, Linthicum, MD 21090, USA William E. Brewer Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter St. Columbia, SC 29208, USA KEYWORDS DPX, LC/MS/MS, Sample Preparation, High Throughput Lab Automation ABSTRACT This work demonstrates the use of disposable pipette extraction (DPX) as a fast and automated sample preparation technique for the determination of barbiturates and 11-nor-9- carboxy- 9-THC (COOH-THC) in urine. Using a GERSTEL MultiPurpose Sampler (MPS) with DPX option coupled to an Agilent 6460 LC-MS/MS instrument, 8 barbiturates and COOH-THC were extracted and their concentrations determined. The resulting average cycle time of 7 min/ sample, including just-in-time sample preparation, enabled high throughput screening. Validation results show that the automated DPX-LC/ AppNote 1/2013 MS/MS screening method provides adequate sensitivity for all analytes and corresponding internal standards that were monitored. Lower limits of quantitation (LLOQ) were found to be 100 ng/mL for the barbiturates and 10 ng/mL for COOH-THC and % CVs were below 10 % in most cases. INTRODUCTION The continuously growing quantity of pain management sample extract for injection [1-2]. The extraction of the drugs used has increased the demand from toxicology Barbiturates and COOH-THC is based on the DPX-RP- laboratories for more reliable solutions to monitor S extraction method described in an earlier Application compliance in connection with substance abuse and/or Note detailing monitoring of 49 Pain Management diversion.
    [Show full text]
  • And Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav™)
    Louisiana Medicaid Sodium Oxybate (Xyrem®) and Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav™) The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request clinical authorization for sodium oxybate (Xyrem®) and calcium, magnesium, potassium and sodium oxybates (Xywav™). These agents have Black Box Warnings and are subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations. Please refer to individual prescribing information for details. Approval Criteria • The recipient is 7 years of age or older on date of request; AND • The recipient has a documented diagnosis of narcolepsy or cataplexy; AND • The prescribing provider is a Board-Certified Neurologist or a Board-Certified Sleep Medicine Physician; AND • By submitting the authorization request, the prescriber attests to the following: o The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; AND o All laboratory testing and clinical monitoring recommended in the product prescribing information have been completed as of the date of the request and will be repeated as recommended; AND o The recipient has no inappropriate concomitant drug therapies or disease states. Duration of initial authorization approval: 3 months Reauthorization Criteria • The recipient continues to meet all initial approval criteria; AND
    [Show full text]
  • Prescription Drug Management
    Check out our new site: www.acllaboratories.com Prescription Drug Management Non Adherence, Drug Misuse, Increased Healthcare Costs Reports from the Centers for DiseasePrescription Control and Prevention (CDC) say Drug deaths from Managementmedication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription Nondrugs. Adherence,1 Drug Misuse, Increased Healthcare Costs The CDC analysis found that nearly 40,000 drug overdose deaths were reported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths from illegal street drugs. Abuse of painkillers like ReportsOxyContin from and the VicodinCenters forwere Disease linked Control to the and majority Prevention of the (CDC) deaths, say deaths from according to the report.1 medication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription drugs. 1 A health economics study analyzed managed care claims of more than 18 million patients, finding that patients undergoing opioid therapyThe CDCfor chronic analysis pain found who that may nearly not 40,000 be following drug overdose their prescription deaths were regimenreported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths have significantly higher overall healthcare costs. from illegal street drugs. Abuse of painkillers like OxyContin and Vicodin were linked to the majority of the deaths, according to the report.1 ACL offers drug management testing to provide information that can aid clinicians in therapy and monitoring to help improve patientA health outcomes.
    [Show full text]
  • Abecarnil/Allobarbital 959 Pharmacopoeias
    Abecarnil/Allobarbital 959 Pharmacopoeias. In Eur. (see p.vii). acamprosate’s action including inhibition of neuronal hyper- maleate in the treatment of anxiety disorders, hiccups, and nau- Ph. Eur. 6.2 (Acamprosate Calcium). A white or almost white excitability by antagonising excitatory amino acids such as sea and vomiting. Acepromazine, as the base, has also been giv- powder. Freely soluble in water; practically insoluble in alcohol glutamate. en in preparations for the management of insomnia. and in dichloromethane. A 5% solution in water has a pH of 5.5 1. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacol- Preparations to 7.0. ogy and clinical potential in the management of alcohol depend- ence after detoxification. Drugs 1997; 53: 1038–53. Proprietary Preparations (details are given in Part 3) Adverse Effects 2. Anonymous. Acamprosate for alcohol dependence? Drug Ther Denm.: Plegicil; Turk.: Plegicil. The main adverse effect of acamprosate is dosage-related diar- Bull 1997; 35: 70–2. Multi-ingredient: Fr.: Noctran. rhoea; nausea, vomiting, and abdominal pain occur less frequent- 3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (suppl ly. Other adverse effects have included pruritus, and occasionally 20): 42–8. a maculopapular rash; bullous skin reactions have occurred rare- 4. Overman GP, et al. Acamprosate for the adjunctive treatment of Aceprometazine (rINN) ly. Depression and fluctuations in libido have also been reported. alcohol dependence. Ann Pharmacother 2003; 37: 1090–9. Hypersensitivity reactions including urticaria, angioedema, and 5. Anton RF, et al. Combined pharmacotherapies and behavioral 16-64 CB; Aceprometazina; Acéprométazine; Aceprometazi- anaphylaxis have been reported very rarely.
    [Show full text]
  • Smumedical Journal
    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062165 B. Purpose for Submission: New device C. Measurand: Barbiturates D. Type of Test: Qualitative and semi-quantitative enzyme immunoassay E. Applicant: Ortho-Clinical Diagnostics, Inc. F. Proprietary and Established Names: VITROS Chemistry Products BARB Reagent VITROS Chemistry Products Calibrator 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, III, IV and V G. Regulatory Information: 1. Regulation section: 21 CFR 862.3150, Barbiturates test system 21 CFR 862.3200, Clinical Toxicology Calibrator 21 CFR 862.3180, Clinical Toxicology Control 2. Classification: Class II, (reagent, calibrator) Class I, reserved (control) 3. Product code: DIS, DLJ and DIF 4. Panel: Toxicology (91) 1 H. Intended Use: 1. Intended use(s): See Indications for use. 2. Indication(s) for use: VITROS Chemistry Products BARB Reagent: For in vitro diagnostic use only. VITROS Chemistry Products BARB Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi- quantitative or qualitative determination of barbiturates (BARB) in human urine using a cutoff of 200 ng/mL or 300 ng/mL. Measurements obtained with the VITROS BARB method are used in the diagnosis and treatment of barbiturates use or overdose. The VITROS Chemistry Products BARB assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result with this assay. Gas Chromatograpy/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]